COMP <GO>
TWST vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Twist Bioscience Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TWST 4
— ABBV 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: TWST
LAST: $173.45 (0.00%) • MKT CAP: $11.50B
balance-sheet
26.00
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWST VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TWST | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 94.20% | 70.20% | +24.00 | TWST | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.70% | 29.00% | -40.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.66% | 3.47% | -4.13 | ABBV | /fcf-yield <GO> |
| Operating Margin | -4.20% | 24.60% | -28.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -2.40% | 6.90% | -9.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 8.60% | +7.90 | TWST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 5.33 | +20.67 | TWST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.2 | 65.1 | -7.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.15 | -0.17 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 113.1x | -92.10 | TWST | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.50B | $513.86B | -$502.36B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TWST REV | ABBV REV | TWST GROSS % | ABBV GROSS % | TWST FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | -$75.6M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$69.2M | $17.83B |
| FY 2023 | $0 | $54.32B | — | — | -$142.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWST // BETA 0.98
ABBV // BETA 1.15